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Abstract
Background: The Angiotensin Converting Enzyme (ACE) insertion/deletion (I/D) polymorphism
has received much attention in pharmacogenetic research because observed variations in response
to ACE inhibitors might be associated with this polymorphism. Pharmacogenetic testing raises the
hope to individualise ACE inhibitor therapy in order to optimise its effectiveness and to reduce
adverse effects for genetically different subgroups. However, the extent of its effect modification
in patients treated with ACE inhibitors remains inconclusive. Therefore our objective is to quantify
the effect modification of the insertion/deletion polymorphism of the angiotensin converting
enzyme gene on any surrogate and clinically relevant parameters in patients with cardiovascular
diseases, diabetes, renal transplantation and/or renal failure.
Methods: Systematic Review. We will perform literature searches in six electronic databases to
identify randomised controlled trials comparing the effectiveness and occurrence of adverse events
of ACE inhibitor therapy against placebo or any active treatment stratified by the I/D gene
polymorphism. In addition, authors of trials, experts in pharmacogenetics and pharmaceutical
companies will be contacted for further published or unpublished data. Hand searching will be
accomplished by reviewing the reference lists of all included studies. The methodological quality of
included papers will be assessed. Data analyses will be performed in clinically and methodologically
cogent subgroups. The results of the quantitative assessment will be pooled statistically where
appropriate to produce an estimate of the differences in the effect of ACE inhibitors observed
between the three ACE genotypes.
Discussion: This protocol describes a strategy to quantify the effect modification of the ACE
polymorphism on ACE inhibitors in relevant clinical domains using meta-epidemiological research
methods. The results may provide evidence for the usefulness of pharmacogenetic testing for
individualised ACE inhibitor therapy.
Background
Research in genetics and genome sequencing has led to a
better understanding of the molecular genetic mecha-
nisms and to the detection of inter-individual genetic
differences, so-called polymorphisms, which may have a
functional consequence on the response to drugs. Phar-
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macogenetic tests provide information to better predict
and prevent therapeutic failures and adverse drug reaction
and raise the hope for an individualised pharmacotherapy
[1-3]. Although pharmacogenetic research has moved
into several branches of medicine such as cardiology [4],
oncology [5] and respiratory medicine [6], the implemen-
tation of pharmacogenetic testing into clinical practice is
still at the very beginning [7].
The ACE polymorphism identified in 1990 by Rigat and
co-workers [8] is one of the best-researched polymor-
phisms. This polymorphism of the ACE gene is based on
the presence or absence of a 287-bp element on intron 16
on chromosome 17. Rigat et al. have shown that the level
of circulating ACE enzymes depends on the insertion/
deletion (I/D) polymorphism. Since then it has been spec-
ulated that these differences in plasma ACE activity asso-
ciated with the ACE genotype might affect the therapeutic
response of ACE inhibitors explaining interindividual var-
iability in cardiovascular or renal response to equivalent
doses of ACE inhibitors [9]. Several studies have investi-
gated the extent of this effect modification on response to
ACE inhibitors for different indications such as hyperten-
sion [10], diabetic nephropathy [11,12] and coronary
artery disease [4,13]. There are however inconsistencies in
trial findings [14-16] and as a result the extent of effect
modification of this polymorphism remains unclear.
Therefore, our objective is to systematically review all ran-
domised controlled trials that assessed to what extent the
insertion/deletion polymorphism of the angiotensin con-
verting enzyme gene influences the effect and adverse
events of angiotensin converting enzyme inhibitors on
any surrogate and clinically relevant parameters in
patients with cardiovascular disease, diabetes, renal trans-
plantation and/or renal failure.
Methods
Search strategy
We will perform literature searches in (Pre-) MEDLINE
(DataStar version, Cary North Carolina), EMBASE
(DataStar version, Cary North Carolina), Biosis (Ovid ver-
sion "Previews 1989 to 2003", New York, New York), the
Cochrane Controlled Trials Register (CCTR <3rd Quarter
2003>, Oxford, United Kingdom) and the Science citation
index. A preliminary literature search in Medline has been
carried out to estimate the range of relevant literature. Out
of the citations of the pilot searches (172 citations) we
identified articles that met our inclusion criteria. Key-
words of these articles were used to refine our search strat-
egies. In collaboration with an information specialist we
designed the final search strategies for the six databases
avoiding any language restrictions [see additional file 1:
the search strategies].
In addition, authors of trials identified in the literature
search will be contacted for additional published or
unpublished data. Particular efforts will be made to
obtain unpublished data on genetic test information and
effect measures stratified according to the genetic subtypes
examined. We will send our requests and subsequent
reminders for additional data to the first and last authors.
Other contacts will include the relevant collaborative
review groups of the Cochrane Collaboration, pharma-
ceutical companies and manufacturers and researchers
known to have published pharmacogenetic analyses in
the area of cardiovascular disease, diabetes, renal trans-
plantation and/or renal failure. Hand searching will be
accomplished by reviewing the bibliographies of all
included studies to identify additional relevant articles as
well as by using the "related articles" function of PubMed
and the citation index of ISI Web of Science.
Anticipating that subgroup analyses investigating gene
polymorphisms may not be specifically mentioned in
titles or abstracts, we will study the full text of all ran-
domised placebo-controlled trials (RCT) that assessed the
effectiveness of ACE inhibitors in order to identify sub-
group analyses investigating gene polymorphisms.
Inclusion criteria
Two reviewers will independently assess all obtained titles
and abstracts of the literature search for inclusion. The cri-
teria to be used to identify relevant studies will be 1) ran-
domised controlled trials 2) the investigation of an
angiotensin converting enzyme inhibitor used for one of
the clinical domains mentioned below and 3) the deter-
mination of the deletion/insertion polymorphism of
patients.
The two reviewers will then examine the full texts of all
potentially relevant citations. The decision on in- and
exclusion will be based on the following, more explicit
inclusion criteria.
Clinical domains
We will include studies investigating ACE inhibitors in the
four major clinical domains namely cardiovascular dis-
eases, diabetes, renal transplantation and/or renal failure.
Patients
Studies should include patients with the following indica-
tions for ACE inhibitor therapy: Heart failure, primary
and secondary hypertension, coronary artery disease, dia-
betic nephropathy, primary nephropathy and status after
renal transplantation.BMC Medical Genetics 2004, 5:23 http://www.biomedcentral.com/1471-2350/5/23
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Intervention
All licensed or unlicensed ACE inhibitors identified
through the literature search will be included.
We will prefer placebo as control intervention in order to
study the effect modification. However to assess all avail-
able evidence, we will also include pragmatic trials where
patients with active treatments (e.g. usual care with any
antihypertensive medication) served as controls.
Co-intervention
We are mainly interested in studies investigating a single
drug exposure with ACE-inhibitors. However we will also
include those studies, which allowed co-medications.
Description of the pharmacogenetic test
Studies must include a description on how determination
of the angiotensin converting enzymes genotypes (DD/
DI/ II) has been performed. If a study does not report
details of testing but provides relevant results, authors will
be contacted to obtain information of testing technique.
Outcomes
We will secure data on any reported outcome, surrogate
endpoints (e.g. decrease in blood pressure, changes in
hemodynamic parameters, proteinuria, creatinine levels,
microalbuminuria) and clinically relevant outcomes (e.g.
total and disease specific mortality, morbidity (none fatal
myocardial infarction, reinfarction, stroke, transient
ischemic attack, rehospitalisation kidney failure or end-
stage renal disease)).
The two reviewers will resolve any discrepancies about in-
or exclusion by discussion. If agreement cannot be
achieved, a third reviewer will make the decision.
Data extraction strategy
We will use a pre-designed data extraction form that
includes different items to assess the studies' external
validity [see additional file 2: Data extraction and quality
assessment sheet]. Details on study design, treatment,
patients and pharmacogenetic tests as well as outcome
parameters will be registered onto the data extraction
form independently by two reviewers. Also, bibliographic
details such as author, journal, year of publication and
language, will be registered. This list will be pre-tested on
a small sample of included and excluded studies address-
ing the appraisal topic. A third reviewer will resolve any
discrepancies. The data extraction shows the extent of
insufficient reporting and authors will be contacted to
obtain missing information.
Quality assessment strategy
All trials included in the review will be assessed using a list
of selected quality items indicating components of inter-
nal validity and descriptive information [17]. In principle
these selected items will enable us to define any process at
any stage of inference tending to produce results that dif-
fer systematically from the true values (bias) [18]. We will
also assess additional methodological aspects that might
bias the results of pharmacogenetic studies (e.g. blinding
of laboratory assessor of outcomes, blinding of outcome
assessor for genotypes, blinding of treatment provider for
genotypes. See Data extraction and quality assessment
sheet).
In addition, we will assess the description of the methods
to determine genotypes. Angiotensin converting enzymes
genotypes (DD/ DI/ II) are traditionally determined using
polymerase chain reaction (PCR) amplification according
to previously published protocols [19]. The D allele is
preferentially amplified; therefore each sample found to
have the DD genotype should be confirmed in a second
independent PCR amplification by the use of an insertion
specific primer to avoid the misclassification of the 4–5
percent of samples with DI genotypes as DD genotypes
[19]. Beyond the use of the standard PCR with/without
the second round of PCR using an insertion-specific
primer, there is also a "tri-primer" method, which has
been shown to be the proper method to be used in geno-
typing ACE I/D polymorphism [20]. The methodology of
the ACE genotyping will be considered as an explanatory
variable for heterogeneity between studies [see additional
file 2: Data extraction and quality assessment sheet].
We will pre-test these quality assessment items on a small
sample of studies in duplicate and if necessary add miss-
ing descriptive items.
Two reviewers will independently score the internal and
descriptive validity. The initial degree of discordance
between the reviewers will be reported. Discordant scores
based on obvious reading errors will be corrected. Dis-
cordant scores based on real differences in interpretation
will be resolved through consensus. A third party will be
sought if necessary. The reviewers will not be blinded for
names of authors, institutions, journals or the outcomes
of the studies.
These detailed quality assessment will be used to describe
the methodological quality of selected studies, to explore
potential sources of heterogeneity, to make informed
decisions regarding suitability of meta-analysis and to
weigh the strength of any conclusions.
Methods of analysis and synthesis
Description of data
The results of the data extraction and assessment of study
validity will be presented in different structured tables and
in a narrative description [see additional file 2: DataBMC Medical Genetics 2004, 5:23 http://www.biomedcentral.com/1471-2350/5/23
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extraction and quality assessment sheet]. This will allow
us to display variation in patient characteristics, study
quality and results. Thus, the description will include the
details about the clinical domain in which the ACE inhib-
itors have been assessed, information about the study
design and quality, a list reporting co-interventions dur-
ing the study period, details about the study population
(baseline characteristics, e.g. severity of disease, ethnic
groups, environmental and social characteristics) and a
description of the outcome measures that were applied.
Finally the tables will provide the individual study results
(all reported outcomes) of the different genotypes in the
intervention and control group. Continuous outcomes
(e.g. blood pressure) will be summarised in the table as
mean differences between baseline and follow up meas-
ures. For data of dichotomous outcomes (e.g. cardiovas-
cular death) the relative risks between the results of the
DD genotype and the II genotype will be calculated and
described in the table. A relative risk of one indicates no
difference between two genotypes, where as relative risks
Example of analysis using virtual data Figure 1
Example of analysis using virtual data. Forest plot: For clinically and methodologically cogent subgroups weighted mean differ-
ences (95% confidence interval) for reduction of systolic blood pressure in patients with hypertension have been assessed. This graph dis-
plays differences of the ACE inhibitor effect within genotypes. The diamonds below each of the three genotypes indicate the pooled 
results. The lowest (forth) diamond reflects the overall effect of ACE inhibitors across all genotypes. In this example, the DD genotype 
shows the largest ACE inhibitor effect and the II genotype shows the smallest effect. The size of the box is related to the number of stud-
ied patients.
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lower respectively higher than 1 indicates variations in the
treatment effect.
Heterogeneity assessment
The heterogeneity assessments help us to examine study
characteristics that might be related to variability in the
observed outcome. Within each subgroup potential
sources of heterogeneity that may affect the imprecision in
the estimate of treatment effect such as the study method-
ology, population characteristics, intensity of interven-
tion, co-medications and risk factors will be examined.
We will perform multiple linear regression analyses
(meta-regression) to explore sources of between-study
heterogeneity. The log transformed odds ratio for dichot-
omous outcomes (myocardial infarction) and continuous
outcomes (blood pressure) measurements will be used as
dependent variables and the clinical and methodological
items of the extraction sheet as described above will be
entered into the model as independent variables.
When a factor is strongly associated with the variation in
ln odds ratio or on the continuous outcome, we will strat-
ify the studies on that variable and inspect residual heter-
ogeneity using forest plots.
If a meta-analysis seems appropriate, that is when the p-
value of the chi-squared test for heterogeneity is greater
than 0.10, a fixed effects model will be used for pooling.
Within clinically and methodologically cogent subgroups
relative risks for dichotomous outcomes and weighted
mean differences for continuous outcomes will be calcu-
lated comparing the contrast between the intervention
and the control group within genotypes. The results
between the different genotypes will be presented in a for-
est plot as shown in Figure 1 and differences will be statis-
tically assessed.
The pooled results of a cogent subgroup will produce an
estimate of the differences in the average effect of ACE
inhibitors observed between ACE genotypes. Thus the
treatment effect of each genotype could be compared to
the overall effect of ACE inhibitors regardless of the
genotype.
All statistical analyses will be performed using the Stata
statistical software package (StataCorp. 2004. Stata® Statis-
tical Software: Release 8.2 College Station, Texas, USA).
Discussion
This review shows an efficient approach to quantify the
effect modification of the ACE polymorphism on ACE
inhibitors when applied in different clinical occasions.
We aim to resolve part of the controversy in the literature
by quantifying the influence of the three genotypes (DD/
DI/II) on different outcomes and in the light of study
methodology and participants characteristics. These
results should inform clinicians about the potential of
pharmacogenetic testing to individualise ACE inhibitor
treatment.
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